富含亮氨酸α-2糖蛋白1通过人表皮生长因子受体3信号促进转移性结直肠癌生长
该研究探讨肝内皮细胞分泌的LRG1如何以非经典方式激活结直肠癌细胞HER3并促进转移性结直肠癌生长。体外和多种小鼠模型显示,LRG1直接结合并激活HER3,敲除LRG1或使用中和抗体可抑制肝内转移瘤生长并延长小鼠生存。LRG1-HER3下游为PI3K-PDK1-RSK-eIF4B轴,常规HER3抗体不能阻断该通路。
要点
- 肝内皮细胞分泌的LRG1是HER3的新型配体,可不依赖神经调节蛋白激活HER3。
- 基因敲除或中和抗体阻断宿主LRG1可抑制小鼠肝内转移性结直肠癌生长并延长生存。
- LRG1-HER3下游信号为PI3K-PDK1-RSK-eIF4B轴,常规HER3抗体不能阻断。
核心结论
- LRG1是新型HER3配体并介导肝脏与转移性结直肠癌之间的交互作用。
- LRG1-HER3信号轴不同于经典HER3信号,为治疗转移性结直肠癌及可能其他肝转移提供新治疗机会。
研究设计与样本
- 研究使用患者来源的原代肝内皮细胞探究内皮细胞与结直肠癌细胞的交互作用。
- 通过蛋白质组学分析鉴定内皮细胞分泌的触发结直肠癌非经典HER3激活的因子。
- 使用多种小鼠转移性结直肠癌模型确定该因子对转移性结直肠癌的后续效应。
- 采用基因和药理干预的体外研究绘制非经典HER3通路。
主要发现
- 内皮细胞分泌的LRG1直接结合并激活HER3,促进结直肠癌生长,与经典HER3配体神经调节蛋白不同。
- 通过基因敲除或中和抗体阻断宿主来源LRG1,可损害肝内转移性结直肠癌生长并延长小鼠生存。
- LRG1-HER3相互作用下游的生物学相关信号级联为PI3K-PDK1-RSK-eIF4B轴激活的蛋白质合成。
- 常规HER3特异性抗体不能阻断该通路,这些抗体在既往临床试验中失败。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Therapy failure in patients with metastatic colorectal cancer (mCRC, ∼80% occur in the liver) remains an overarching challenge. Preclinical studies demonstrated that human epidermal growth factor receptor 3 (HER3) promotes colorectal cancer (CRC) cell survival, but therapies blocking the neuregulin-induced canonical HER3 signaling have made little impact in the clinic. Recent studies suggest that the liver microenvironment promotes CRC growth by activating HER3 in a neuregulin-independent fashion, thus elucidation of these mechanisms may reveal new strategies for treating patients with mCRC. METHODS: Patient-derived primary liver endothelial cells (ECs) were used to interrogate EC-CRC crosstalk. We conducted proteomic analysis to identify EC-secreted factor(s) that triggers noncanonical HER3 activation in CRC and determined the subsequent effects on mCRC using diverse murine mCRC models. In vitro studies with genetic and pharmacological interventions were used to map the noncanonical HER3 pathway. RESULTS: We demonstrated that EC-secreted leucine-rich alpha-2-glycoprotein 1 (LRG1) directly binds and activates HER3 and promotes CRC growth distinct from neuregulin, the canonical HER3 ligand. Blocking host-derived LRG1 by gene knockout or a neutralizing antibody impaired mCRC outgrowth in the liver and prolonged mouse survival. We identified protein synthesis activated by the PI3K-PDK1-RSK-eIF4B axis as the biologically relevant signaling cascade downstream of the LRG1-HER3 interaction, which was not blocked by conventional HER3-specific antibodies that failed in prior clinical trials. CONCLUSIONS: LRG1 is a novel HER3 ligand and mediates liver-mCRC crosstalk. The LRG1-HER3 signaling axis is distinct from canonical HER3 signaling and represents a new therapeutic opportunity to treat patients with mCRC, and potentially other types of liver metastases.
引用
- Rathore M, Curry K, Huang W, et al. Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling. Gastroenterology. 2024. PMID: 39393543. doi:10.1053/j.gastro.2024.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。